Q-omics provides the consensus-scored SLC6A7 profile across patient tissues and cancer cell-line models. SLC6A7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC6A7 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SLC6A7 protein abundance shows 18,796 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where SLC6A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A7 survival associations across molecular data types. SLC6A7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A7 RNA expression–survival associations across cancer types. High SLC6A7 expression shows unfavorable associations in KIRC, ACC and CESC, but favorable associations in HNSC, SKCM and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC6A7 RNA expression.
This table summarizes SLC6A7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC6A7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A7 shows higher tumor expression in HNSC, STAD, KIRC, LIHC, LUAD and BLCA. The HNSC box plot shows higher SLC6A7 RNA expression in tumor versus normal tissue (log2 FC = +0.132, t-test p < 0.001).
This table shows molecular features associated with SLC6A7 in patient tissues and cancer cell lines. In patient samples, SLC6A7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
